English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Extracellular tau is hypothesized to mediate the onset and progression of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and a subset of frontotemporal lobar degenerations. A putative strategy for treating these disorders is to reduce extracellular tau levels using tau‐directed immunotherapy. The results of the first‐in‐human study of BIIB092 (formerly BMS‐986168/IPN007), a humanized monoclonal antibody that binds to N‐terminal tau, are reported here. This randomized, double‐blind, single ascending dose study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity profile of BIIB092 after a single intravenous infusion in healthy participants.    Methods  Sixty‐five participants were randomized to receive a single intravenous infusion of placebo or BIIB092 at doses of 21, 70, 210, 700, 2100, or 4200 mg (or 700 or 2100 mg for Japanese participants). Serial blood and cerebrospinal fluid samples were obtained for assessment of pharmacokinetic parameters and unbound N‐terminal tau suppression.    Results  There were no deaths, serious adverse events (AEs), severe AEs, or discontinuations due to an AE. The majority of AEs were mild. Serum BIIB092 concentrations increased in a dose‐proportional manner and suppressed unbound cerebrospinal fluid N‐terminal tau by 67%–97% at 28 days after dose, with doses of ≥210 mg producing persistent unbound N‐terminal tau suppression over 12 weeks. Levels of cerebrospinal fluid N‐terminal tau suppression were similar for Japanese and non‐Japanese participants.    Discussion  BIIB092 was generally safe and well tolerated after a single dose of up to 4200 mg, and up to 2100 mg in Japanese participants. BIIB092 exhibited a dose‐dependent increase in the extent and duration of unbound N‐terminal tau suppression.

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants